Treatment of Malaria with Oral or Intravenous Plaquenil

Abstract

Summary Eighty-two Hondurans were treated for malaria with 7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino] quinoline diphosphate (Plaquenil). Sixty-eight of them (21 with P. falciparum, 47 with P. vivax) were given a single oral dose of 1.25 gm. Fourteen others with P. falciparum infections were given an intravenous dose of 0.36 gm. in 500 cc. of normal saline solution. Both the immediate and the late results were encouraging. Toxic side-effects of the drug were not encountered. Plaquenil, therefore, warrants further investigation; its experimental use will be continued in this and other locations.